Lowenstein Sandler represented 645 Ventures, a New York-based venture capital company, as lead investor in a $6.05 million Series Seed fund raise in InpharmD, an Atlanta, GA-based provider of an AI-based drug information service.
Other investors included Atlanta Ventures, Y Combinator, Qlarant Capital, SF ELC, and angels.
The company intends to use the funds to expand operations and its business reach.
InpharmD facilitates evidence-based care by making on-demand drug information accessible, using artificial intelligence (AI) combined with pharmacists’ expertise to make custom, data-driven responses to clinical questions and formulary requests. Additionally, it supports cost-efficient decision-making by suggesting data-driven therapeutic interchanges and protocols that reduce patient hospital stays.
The Lowenstein deal team included Chandra K. Shih, Rahul J. Devnani, and Spencer Kau.
